Loading…
← CockpitCompetitor Analysis › 4516.T Nippon Shinyaku Co., Ltd.Open in the cockpit ↗

Nippon Shinyaku Co., Ltd.4516.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Pharmaceuticals: Major

Japanese pharmaceutical company focused on rare/orphan diseases, urology and respiratory drugs.

≈ A mid-size Japanese pharma with a rare-disease focus, like a smaller AlexionMomentum weak 30
Mkt cap
$1.42B
US dollars, full cap
Free float
71%
of shares outstanding
$/day
$7.83M
20-day average traded
Fwd P/E
7.9×
forward earnings
ROIC−WACC
+5.5 pp
WACC 5.0%
Hurdle
-25 pp
Req g minus delivered
Next earnings
79 days
5 Feb 2027
Close · JPY¥3,377
1D-1.3%
1W-0.4%
1M-1.3%
3M-7.2%
6M-20.3%
YTD-40.2%
1Y+3.3%
ATR %2.2%
52w lowhigh48.3% off high

What Nippon Shinyaku does

Japanese pharmaceutical company focused on rare/orphan diseases, urology and respiratory drugs.

Sells prescription drugs to hospitals and specialist doctors, largely in Japan, and earns outside Japan through its US subsidiary NS Pharma, which markets Viltepso for Duchenne muscular dystrophy. A smaller functional-food ingredients business sits alongside the drugs.

In one line: A mid-size Japanese pharma with a rare-disease focus, like a smaller Alexion.

Products and services

  • Rare/orphan disease drugs
  • Urology drugs
  • Respiratory drugs

Customers

  • Hospitals/specialists prescribing its drugs
  • Patients

Where it sits in the supply chain

  • Health care
  • Pharmaceuticals
  • Rare disease, urology and respiratory…

What could go right

  • Orphan drug pipeline progress/approvals

What could go wrong

  • Clinical trial failure risk
  • Patent cliffs

Moat: narrow (IP / patents, regulatory licence). Orphan-drug designations and patents provide extended exclusivity in niche therapeutic areas.

Headquarters: Kyoto, Japan · Founded: 1919 · Employees: 2,309

Named competitors

Nippon Shinyaku at a glance

Size Nippon Shinyaku (4516.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $1.42B, the 591st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,377 on 18 Nov 2026.

Performance Over six months the shares fell 20.3%, against -9.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th lowest of 20 in its peer set.

Growth Revenue grew 17.7% over the last twelve months (peer median +11.3%); the operating margin is 17.8% (peer median 10.2%).

Valuation It trades at 7.9× forward earnings against a peer median of 23.2× (cheapest of 10).

Price implies For today's price to make sense, revenue must grow about -18% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -25 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 5.5 points above its cost of capital (5.0% WACC).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 924516.T 80
Six months, rebased to 100: Nippon Shinyaku against the median of its 20 peers (local-currency closes).

Nippon Shinyaku financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥189B¥171B¥160B¥148B¥144B
Revenue growth—+7%+8%+3%—
Gross profit¥122B¥112B¥108B¥97.0B¥87.3B
EBITDA¥40.6B¥39.7B¥42.8B¥36.4B¥34.3B
Net income¥29.4B¥29.7B¥32.6B¥25.9B¥22.8B
Free cash flow¥23.0B¥24.2B¥32.8B¥11.2B¥20.5B
Capital expenditure¥13.0B¥3.78B¥34.8B¥9.65B¥11.7B
Total debt¥3.33B¥2.57B¥2.72B¥2.87B¥2.66B

Quarterly statements and history in the cockpit →

Nippon Shinyaku competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-20%0%+20%DMRAMARKSANS310210140410PAHC002626002020CORONA141080226950NANO298380300181603235002099068760688293MNKD4516.T6-month return →1-month return →
Up and to the right = strong over both horizons. Nippon Shinyaku is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×MARKSANSPAHC002626002020CORONA300181688293MNKD4516.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nippon Shinyaku is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%MARKSANSPAHC002020CORONA3001816032350687606882934516.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Nippon Shinyaku is the large dot.

Nippon Shinyaku competitors and peer comparison

Head to head with its named competitors (4516.T vs 4503.T vs 4528.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Nippon Shinyaku 4516.T$1.42B-20%+18%18%7.9×-18.1%
Astellas Pharma 4503.T$31.4B+17%+19%23%12.9×-9.0%
ONO Pharmaceutical 4528.T$7.33B-2%-2%22%15.3×-6.8%

How Nippon Shinyaku compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nippon Shinyaku against its 20 peers (data as of 18 Nov 2026)
Measure4516.TPeer medianRank in peer set
1-month return-1.3%-3.7%9th highest of 20
6-month return-20.3%-9.1%7th lowest of 20
Distance from 52-week high-48.3%-40.0%8th lowest of 20
Revenue growth (TTM)+17.7%+11.3%5th highest of 19
Operating margin17.8%10.2%6th highest of 19
Forward P/E7.9×23.2×cheapest of 10
Growth the price implies (Req g, 7 yrs)-18.1%3.9%least demanding of 10
Growth delivered (Del g)+7.0%+16.6%4th lowest of 10
Hurdle (Req g minus delivered)-25.1 pp-7.9 ppleast demanding of 10
ROIC minus cost of capital+5.5 pp-1.8 pp6th highest of 20
EV / EBITDA3.9×17.6×cheapest of 5
Net debt / EBITDA-1.7×0.3×least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Nippon Shinyaku 4516.TJapan$1.42B-20%+18%18%7.9×-18.1%+7.0%
Damora Therapeutics DMRAUnited States$1.42B-5%n/an/an/an/an/a
Marksans Pharma MARKSANS.NSIndia$1.43B+36%+24%20%23.2×31.0%+16.6%
Voronoi 310210.KSSouth Korea$1.43B-62%-100%-438,152%n/an/an/a
Mezzion Pharma 140410.KSSouth Korea$1.43B-15%+13%-211%n/an/an/a
Phibro Animal Health PAHCUnited States$1.44B+5%+10%13%9.9×-6.4%+12.7%
Xiamen Kingdomway 002626.SZChina$1.45B-3%-3%11%27.2×n/an/a
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%12.1×-9.6%+4.6%
Corona Remedies CORONA.NSIndia$1.48B+27%+17%18%58.9×36.3%+16.6%
LigaChem Biosciences 141080.KSSouth Korea$1.48B-72%-55%-324%n/an/an/a
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%n/an/an/a
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%n/an/an/a
ABL Bio 298380.KSSouth Korea$1.51B-71%-53%-201%n/an/an/a
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%13.0×3.9%+22.8%
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%n/a-4.9%+0.2%
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%16.0×-6.1%+1.9%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%n/an/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%n/a10.2%+18.1%
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%48.6×25.9%+23.1%
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
MannKind MNKDUnited States$1.31B+25%+32%-2%174.4×n/an/a

Questions

Who are Nippon Shinyaku's main competitors?
Named competitors: Astellas Pharma (4503.T), Ono Pharmaceutical (4528.T), Alexion (AstraZeneca) (private or unlisted). The cockpit's measured peer set (industry) also includes Damora Therapeutics (DMRA), Marksans Pharma (MARKSANS.NS), Voronoi (310210.KS), Mezzion Pharma (140410.KS), Phibro Animal Health (PAHC), Xiamen Kingdomway (002626.SZ).
Is Nippon Shinyaku expensive compared with its peers?
On forward p/e it trades at 7.9× against a peer median of 23.2×, cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about -18% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -25 pp: the price already allows for a slowdown.
How has Nippon Shinyaku stock performed?
Over six months to 18 Nov 2026 the shares returned -20.3% against -9.1% for the median peer; over one year +3.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.